> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly’s Mirikizumab Hits Ulcerative Colitis Trial Endpoints
- URL: https://www.fdaweb.com/lillys-mirikizumab-hits-ulcerative-colitis-trial-endpoints/
- Published: 2021-03-17T12:00:00.000Z
- Updated: 2026-09-14T16:51:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148896

Lilly says its mirikizumab met the primary and all key secondary endpoints in the LUCENT-1 Phase 3 induction study evaluating the drug’s safety and efficacy in treating patients with moderate to severe ulcerative colitis. The company [says](https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-helps-patients-achieve-clinical-remission-and?ref=fdaweb.com) LUCENT-2, a multicenter maintenance study in patients who completed the 12-week LUCENT-1 study is ongoing.

According to Lilly, mirikizumab met the primary endpoint of clinical remission at week 12 compared to placebo. It also met the key secondary endpoints of reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission, and improvement in endoscopic histologic inflammation. It demonstrated rapid improvement in patient symptoms as early as four weeks after starting treatment, the company says.

Mirikizumab is described as a humanized igG4 monoclonal antibody that binds to the p19 subunit of interleukin 23\. It is being studied for the treatment of immune diseases including psoriasis, ulcerative colitis, and Crohn’s disease.